NCT04676607View on ClinicalTrials.gov

SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

June 12, 2023

Study Completion Date

June 12, 2023

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

SHR7390

SHR7390

Trial Locations (1)

210000

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT04676607 - SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter